New antibody injection aims to tackle blinding eye diseases

NCT ID NCT05919693

Completed Disease control Sponsor: EyeBiotech Ltd. Source: ClinicalTrials.gov ↗

First seen Nov 20, 2025 · Last updated Jun 23, 2026 · Updated 21 times

Summary

This study tested a new drug called EYE103, given as an injection into the eye, for people with diabetic macular edema (DME) or wet age-related macular degeneration (NVAMD). The trial had two parts: first, checking safety at increasing doses in about 12 people, then comparing two doses for effectiveness in about 80 people. The main goal was to see if the drug is safe and can improve vision.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NVAMD) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Locations

Abilene, TX

Abilene, Texas, 79606, United States
Amarillo, TX

Amarillo, Texas, 79109, United States
Arecibo, PR

Arecibo, PR, 00612, Puerto Rico
Austin, TX

Austin, Texas, 78705, United States
Bakersfield, CA

Bakersfield, California, 93309, United States
Bellaire, TX

Bellaire, Texas, 77401, United States
Caba, Argentina

Caba, 1023, Argentina
Ciudad Autonoma Buenos Aires

Ciudad Autonoma de Buenos Aires, Buenos Aires, C1121ABB, Argentina
Colorado Springs, Colorado

Colorado Springs, Colorado, 80909, United States
Dallas, TX

Dallas, Texas, 75231, United States
Germantown, TN

Germantown, Tennessee, 38138, United States
Hagerstown, MD

Hagerstown, Maryland, 21740, United States
Katy, TX

Katy, Texas, 77494, United States
Knoxville, TN

Knoxville, Tennessee, 37922, United States
Lakewood, CO

Lakewood, Colorado, 80288, United States
Lemont, NV

Lemont, Illinois, 60439, United States
London, England

London, England, NW10 7NS, United Kingdom
London, UK

London, W1G7LB, United Kingdom
McAllen, TX

McAllen, Texas, 78503, United States
Modesto, CA

Modesto, California, 95356, United States
Mountain View, CA

Mountain View, California, 94040, United States
Nashville, TN

Nashville, Tennessee, 37203, United States
Phoenix, AZ

Phoenix, Arizona, 85032, United States
Plano, TX

Plano, Texas, 75075, United States
Pompano Beach

Pompano Beach, Florida, 33064, United States
Reno, NV

Reno, Nevada, 89502, United States
Round Rock, TX

Round Rock, Texas, 78681, United States
Sacramento, CA

Sacramento, California, 95825, United States
Sacramento, CA

Sacramento, California, 95841, United States
San Antonio, TX

San Antonio, Texas, 78240, United States
The Woodlands, TX

The Woodlands, Texas, 77384, United States
West Columbia, SC

West Columbia, South Carolina, 29169, United States

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

EYE103 (a lab-made antibody given as an eye injection)

What this could lead to

If successful, EYE103 could offer a new treatment option for two common causes of vision loss, potentially reducing the need for frequent eye injections.

What could go wrong

This is an early-phase trial with only 33 participants, so results may not apply to everyone. The drug is injected directly into the eye, which carries risks like infection or inflammation.

Conditions

The condition(s) this trial relates to.

macular degeneration wet macular degeneration

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DIABETIC MACULAR EDEMA (DME) NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NVAMD)